Analysts Issue Forecasts for RNA Q3 Earnings

Key Points

• Roth Capital estimates that Avidity Biosciences will report a Q3 2025 earnings per share of ($1.02), maintaining a "Buy" rating with a price target of $62.00.
• Avidity's average target price among analysts is $68.58, with several firms adjusting their ratings and price targets upwards recently.
• Insider trading activity showed significant sales, with CEO Sarah Boyce and Director Troy Edward Wilson selling shares valued at over $3.9 million combined on September 5th.

Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) - Equities research analysts at Roth Capital issued their Q3 2025 earnings estimates for Avidity Biosciences in a research note issued to investors on Wednesday, September 17th. Roth Capital analyst B. Pachaiyappan expects that the biotechnology company will post earnings of ($1.02) per share for the quarter. Roth Capital currently has a "Buy" rating and a $62.00 target price on the stock. The consensus estimate for Avidity Biosciences' current full-year earnings is ($2.89) per share. Roth Capital also issued estimates for Avidity Biosciences' Q4 2025 earnings at ($0.96) EPS, FY2025 earnings at ($4.09) EPS, Q1 2026 earnings at ($0.98) EPS, Q2 2026 earnings at ($1.01) EPS, Q3 2026 earnings at ($1.05) EPS, Q4 2026 earnings at ($1.09) EPS and FY2026 earnings at ($4.13) EPS.

Several other brokerages also recently issued reports on RNA. Chardan Capital reissued a "buy" rating and set a $75.00 price objective on shares of Avidity Biosciences in a research note on Wednesday, September 10th. HC Wainwright raised their price target on shares of Avidity Biosciences from $68.00 to $87.00 and gave the company a "buy" rating in a report on Friday, September 12th. Sanford C. Bernstein began coverage on shares of Avidity Biosciences in a report on Tuesday, June 24th. They set an "outperform" rating and a $50.00 price target for the company. Needham & Company LLC raised their price target on shares of Avidity Biosciences from $60.00 to $65.00 and gave the company a "buy" rating in a report on Wednesday, September 10th. Finally, Barclays reaffirmed an "overweight" rating and set a $62.00 price target (up from $59.00) on shares of Avidity Biosciences in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating and eighteen have issued a Buy rating to the company. According to MarketBeat, Avidity Biosciences presently has an average rating of "Buy" and an average price target of $68.32.

Avidity Biosciences Stock Performance

RNA traded up $0.07 on Friday, hitting $42.41. 472,470 shares of the company were exchanged, compared to its average volume of 2,080,058. The firm has a market capitalization of $6.19 billion, a P/E ratio of -11.90 and a beta of 0.99. The business's fifty day moving average is $42.11 and its 200 day moving average is $34.23. Avidity Biosciences has a fifty-two week low of $21.51 and a fifty-two week high of $56.00.

Insider Buying and Selling

In other news, insider Steven George Hughes sold 81,434 shares of Avidity Biosciences stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $42.74, for a total value of $3,480,489.16. Following the transaction, the insider owned 38,867 shares of the company's stock, valued at $1,661,175.58. The trade was a 67.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Arthur A. Levin sold 107,500 shares of Avidity Biosciences stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $47.62, for a total transaction of $5,119,150.00. Following the completion of the transaction, the director directly owned 19,650 shares in the company, valued at approximately $935,733. This trade represents a 84.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 540,499 shares of company stock worth $24,814,854. 3.83% of the stock is owned by insiders.

Institutional Trading of Avidity Biosciences

A number of institutional investors have recently added to or reduced their stakes in the business. Osaic Holdings Inc. lifted its stake in shares of Avidity Biosciences by 1,659.1% in the second quarter. Osaic Holdings Inc. now owns 1,636 shares of the biotechnology company's stock worth $48,000 after buying an additional 1,543 shares during the last quarter. Hudson Bay Capital Management LP bought a new position in Avidity Biosciences during the second quarter worth $2,130,000. Tower Research Capital LLC TRC increased its position in Avidity Biosciences by 59.4% during the second quarter. Tower Research Capital LLC TRC now owns 13,009 shares of the biotechnology company's stock worth $369,000 after acquiring an additional 4,850 shares during the period. E Fund Management Co. Ltd. increased its position in Avidity Biosciences by 4.6% during the second quarter. E Fund Management Co. Ltd. now owns 14,163 shares of the biotechnology company's stock worth $402,000 after acquiring an additional 629 shares during the period. Finally, Sofinnova Investments Inc. increased its position in Avidity Biosciences by 53.9% during the second quarter. Sofinnova Investments Inc. now owns 584,801 shares of the biotechnology company's stock worth $16,608,000 after acquiring an additional 204,870 shares during the period.

Avidity Biosciences Company Profile

Avidity Biosciences, Inc, a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial.